INTRODUCTION
The term nmrwteroid was (pregnenolone sulfate is an example of such a steroid), although it is conceivable that neurosteroids with such actions codd play a role in regulating seizure susceptibility.
It has been h o w n since the 1940s, from the pioneering work of Hans Selye, that naturally occurring steroids such as the ovarian steroid progesterone and the adrenal steroid deoxycorticosterone (DOC) can exert anesthetic and anticonvulsant action^.^ Recognizing that some steroids could produce such acute central nervous svstem eTfects. researchers at the pharmaceuti&l company Glaxo identdied the synthetic steroid alphaxolone as having anesthetic properties. In the early 1970s, alphaxolone was marketed as a com~onent of the I intravenous anesthetic agent Althesin, which also included the less potent anesthetic steroid alphadalone acetate, said to increase the solubility of alphax~lone.~ Several years later, the mechanism of action of alphaxolone was defined: it was found to enhance synaptic inhibition via an action on GABA r e c e~t o r s .~.~ A major advance occurred when;aturally occur-I ring metabolites of progesterone and DOC were also found to enhance and directly activate GABA rece~tors.' It was s~e c d a t e d that A I I the anesthetic and hypnotic properties of progesterone and DOC h o w n since the time of Selye were due to their conversion in the body to these metabolites, respectively: allopregnanolone (3a-hydroxy-5a-pregnane-20-one)
and allotetrahydrodeoxycorticosterone (3a,21-dihydroxy-5a-pregnan-20-one; THDOC). At the time. it was recognized that the enzvmes u required for the conversion of the steroid hormone precursors to their active A-ring reduced metabolites are ~r e s e n t in brain so that art of the synthesis of ;he GABA, rece~tor actke steroidicould occur locally. ~" h r e f i r e , the neuroactive steroids allopregnanolone and THDOC came to be referred to as neurosteroids even though it was not believed at the time that their synthesis occurred independently of peripherally synthesized precursor steroid hormones. We now know that all of the enzymes required for the synthesis of the GABA, receptor active steroids from cholesterol are present in the brain.8 It is well recognized that these steroids readily cross the blood-brain barrier. While it is likely that locally synthesized GABA, receptor active steroids play a role in modulating circuit excitability, there is little information on the relative imnortance of de novo local svnthesis ver-L , sus peripheral production of either the active GABA, receptor modulatory steroids (e.g., aUopregnanolone or THDOC) or their precursor hormones (e.g., progesterone or DOC), wbch are converted locally by brain 5a-reductase and 3a-hydroxysteroidoxidoreductase (3a-HSOR).
Nevertheless, it is common to refer to GABA, receptor modulatory steroids such as allopregnanolone and THDOC as neurosteroids, and we will follow that practice here. This chapter reviews the potential roles of such neurosteroids as endoqenous modulators of seizure susceptibility anod also the more limited evidence that they can, under certain circumstances, influence epileptogenesis (transformation of the brain to an ewile~tic state). The hscussion I L of these topics serves as a prelude to the main objective of this chapter, which is to review the evidence supporting the utility of exogenously administered neurosteroid-related agents in u the treatment of epilepsy.
DIVERSITY OF NEUROSTEROIDS AND THEIR BIOSYNTHESIS
A variety of GABA, receptor modulatory neurosteroids are known to be synthesized endogenously (Figs. 77-1 and 77-2). The best recognized of these are the pregnane neurosteroids allopregnanolone and THDOC, whch are produced via sequential A-ring reduction of the steroid hormones progesterone and its 21-hydroxylated derivative deoxycorticosterone by 5a-reductase and 3a-HSOR isoenzymes. In the periphery, the steroid precursors are mainly synthesized in the gonads, adrenal gland, and feto-~lacental unit, but as noted above, svnthesis ofl both of these neurosteroids likely dccurs in the brain from cholesterol or from peripherally derived intermehates including. the steroid U hormone precursors. A-ring reduction can also occur in peripheral tissues such as reproductive endocrine tissues, liver, and shn that are rich in the two reducing. a~tivities.~ Since neu-U rosteroids are highly lipophilic and can readily cross the blood-brain barrier, neurosteroids (cytochl-~me P450 81-hydroxylase) converts progesterone to DOC (deoxycorticosterone), which is the precursor for the neurosteroid THDOC (a~otefrahydrodeoxycorti~8terone). In the brain, this reaction appears to be mainly catalyzed by CYP2D aoen:nzymes, which can also convert dopregnanolone to THDOC, synthesized in peripheral tissues accumulate in the brain and can influence brain function.
The 5P-isomers of allopregnanolone and THDOC have GABA, receptor modulatory activity that is only modestly less potent than that of the corresponding Sa-epimer~.~ A steroid SP-reductase enzyme is distributed widely in vertebrates, including in the gonads, liver, and brain.1° However, whether progesterone or DOC is a substrate, and the extent to which 5P-reduced epimers of allopregnanolone and THDOC are praduced endogenously, is unclear.
The androgenic steroid testosterone differs from progesterone by virtue of a 17-alcohol that replaces the 17-acetyl in progesterone. Testosterone is a substrate for both 5a-reductase and 5P-reductase isoenzyrnes. The product of 5a-reduction of testosterone, 5a-dihydrotestosterone, is hormonally more active than testosterone itself. However, subsequent 3a-reduction leads to 5a-androstanediol (501-androstane-3~17P-diol), which is comparable in potency and efficacy to dopregnanolone as a GABA receptor-positive modulator." 5a-and ~~-An$mstanedio~ are hriher metabolized by 17P-hydroxysteroid dehydrogenase to androsterone and etiocholanolone, respectively, which we considered the major excreted metabolites of testosterone. The obsewation that TSPO ligands enhance neurosteroid production not only c o n h s the key role of TSPO in nemsteroidogenesis, but also suggests that such ligands may have therapeutic utility as an alternative to exogenously administered neurosteroids in situations where it is desirable to increase the level of brain neuro~teroids.~~ In admtion to P45Uscc, 3P-hydroqsteroid dehydrogenase, an enzyme required for the conversion of pregnenolone to progesterone, has been demonstrated in the brain? Thus, the enzymes necessary for in situ synthesis of progesterone from cholestero~ are present in the brain.
In the adrenal, P450c21 (cytochrome P450 21-h~droxylase) converts progesterone to DOC, which is the precursor for the neurosteroid THDOC. The brain also possesses 21-hydroxylase activity, but it expresses only very small amounts of P450c21 mRNA and protein. It appears that cytochrome P450 2D (CYP2D) isoforms, inpartidrar C'YP2D4, present in brain can 21-hydroqlate progesterone to form DOC, which can then be converted to 77 Neurosteroids 989 the GABA, receptor have questioned whether these residues reside at the p subunit-a subunit interfa~e.~' A photo-incorporable analog of the anesthetic etomidate appears to bind at the interface, but binding of this ligand is not competitively inhibited by ne~rosteroids.~' In fact. neurosteroids (at concentrations that produce direct receptor activation) enhance bindmg, presuinably due to allosteric effects transmitted upon interaction with a hfferent site on the receptor. The newer topology models do not bring into proximity the residues in the p and a subunits proposed to constitute the site for direct activation. Therefore, at present, the location of this site is uncertain.
A range of steroid structures have activity as positive modulators of GABA, receptors in line with the hydrophobic surface binding site model. Nevertheless, there are certain strict structural requirements for neurosteroidpositive modulation. A hydrogen bond-donating 3a-hydroxy group on the steroid A-ring and a hydrogen bond-accepting group (typically a keto moiety) on the D-ring at either C20 of the pregnane steroid side chain or C17 of the androstane ring system are critical for positive modulatory activity at GABA, receptor^.^^,^^
The orientation of the C.5 hydrogen group only modestly influences p o t e n~y .~ Stuhes with recombinant GABA. recewtor isoforms inhcate that neurosteroids Lct on kost subunit combination^.^^,^' This distinguishes neurosteroids from benz~diaze~ines, whch only act on GABA, receptors thit contain $2 subunits and do not contain a4 or a6 subunits.
In general, the specific a subunit type may influence neurosteroid efficacy, whereas the y subunit t w e mav affect both the efficacv and (peris~aplicall~/extrasynaPtica~y) since thk $2 subunit is required for synaptic targeting.
These properties cause them to be prime candidates for mediating tonic GABA, receptor current that is activated by ambient concentrations of GABA in the extracellular space. Ambient GABA is believed to result from spillover of svnaoticallv released GABA: conceitrai I tions would increase with high levels of activity of GABAergic interneurons, as occurs during seizures. Tonic GABA, receptor current causes a steady inhibition of neurons and reduces their excitability. Neurosteroids could therefore have a general role in setting the level of excitability and might specifically potentiate tonic inhibition during seizures when ambient GABA may rise. Overall, the robust effect of neurosteroids is likely to be due to their action on both synaptic and perisynaptic/extrasynaptic GABA receotors. orders of magnitude greater. Neurosteroids access the GABA, receptor from the lipophlic plasma membrane. The nonspecific accumulation and removal of the neurosteroids from the membrane are the major factors determining the rates of neurosteroid action when applied to cells via aqueous solution; rates of binding and unbinhng to the receptor are only secondary factors.50 It is noteworthy that intracellular delivery through the plasma membrane is compatible wit11 the autocrine mechanism discussed above. in wlsich the neurosteroids act on the GABA, receptors in the same neurons in which they are produced.
As noted, at high concentrations (>lo pM), neurosteroids can directly activate GABA, receptor channels in the absence of GABA.g51,52
In this respect, neurosteroids resemble barbiturates but not benzo&a~ewines.~~ Given the L high concentrations required, whether direct actions are relevant to the role of endogenous neurosteroids or to the pharmacological actions of exogenously administered neurosteroidrelated agents is not well understood.
ANTICONVULSANT AND ANTlEPlLEPTOGENlC EFFECTS OF NEUROSTEROIDS
Exogenously administered neurosteroids, like other agents that act as positive GABA, receptor modulators, e A b i t broad-s~ectruin anti-I convulsant effects in &verse rodent seizure models. They protect against seizures induced by GABA, receptor antagonists includmg pentylenetetrazol (PTZ) and bicuculline, and they are effective against pilocarpine-induced limbic seizures and seizures in londled a n i n~a l s .~~~~~~ However, neurosteroids may exacerbate generalized absence ~e i z u r e s .~~,~~ The potencies of neurosteroids in models where they confer seizure protection vary largely in accordance with their activities as positive allosteric modulators of GABA, receptors. Thus, allopregnanolone has roughly equal potency to THDOC, but androstanediol. androsterone. and etiocholanolone are somewhat less ~o t e n t . However, neurosteroids, acting at distinct sites on GABA* receptors and exhibiting effects on the full range of GABA, receptor isoforms, do not exhibit anticonvulsant tolerance. The sulfated neurosteroids pregnenolone sulfate and dehydroepiandosterone sulfate, which act as GABA, receptor antagonists, are pro-convulsant when administered at high doses into the brain, producing seizures and status e p i l e p t i c u~.~~~'~ Colnpelling evidence that such steroids exist endogenously in the brain is laclang, and in any case it is unlikely that they exist at sufficiently high concentrations to exert pro-convulsant effects, so the physiological relevance is unclear. However, it is known that the seizure-facilitating effects of these steroids can be blocked by coadministration of allopregnanolone or other neurosteroids that positively modulate GABA. r e c e~t o r s .~~ n L In addition to anticonvulsant activity, there is some limited evidence that endogenous neurosteroids play a role in regulating epileptogene~is.'~~~~ Following pilocarpineinduced status epilepticus in the rat, the neurosteroidogenic enzyme P450scc is upregulated for several weeks, suggesting that neurosteroidogenesis may be increased. Ordinarily, rats develop spontaneous recurrent seizures following a latent period of similar duration to the period during which P450scc is elevated. Inhibiting neurosteroid synthesis with finasteride accelerated the onset of spontaneous recurrent seizures, suggesting that endogenous neurosteroids play a role in restraining epileptogenesis or at least that they inhibit the expression of seizures. Exogenous treatment with neurosteroids or with progesterone, whch serves as a precursor for neurosteroid synthesis, has also been reported to delay the occurrence of epileptogenesis in some situations." In fact, progesterone may impair epileptogenesis in lundling models, even at doses that do not affect seizure expre~sion.~~," If endogenous neurosteroids can be confirmed as endogenous regulators of epileptogenesis, neurosteroids themselves or modulators of neurosteroid disposition could potentially have disease-modfying therapeutic activity.
ROLE OF ENDOGENOUS NEUROSTEROIDS IN THE MODULATION OF SEIZURES
Endogenous neurosteroids may play a role in the physiological regulation of seizure susceptibility in indviduals with epilepsy. We will discuss several such situations: catamenial epilepsy, stress, temporal lobe epilepsy, and alcohol withdrawal. However, it is noteworthy that there is no evidence that alterations in neurosteroid levels in the absence of preexisting epilepsy can induce epileptogenesis.
Neurosteroids in Catamenial Epilepsy
CatameniaI epilepsy, the cyclical occurrence of seizure exacerbations during particular phases of the menstrual cycle in women with preexisting epilepsy, is a specific form of pharmacoresistant epilepsy. Catamenial seizure exacerbations affect up to 70% of women of childbearing age with epilepsy.7a0 Although there are several forms of catamenial epilepsy, neurosteroids have been implicated only in the seizure exacerbations that occur in the most common situation, which is when women with normal menstrual cycles experience seizure exacerbations in the perimenstrual period. It is hypothesized that withdrawal of progesteronederived neurosteroids leads to enhanced brain excitability predisposing to seizures.
During the menstrual cycle, circulating progesterone levels are low in the follicular phase but rise in the midluteal phase for about 10 to 11 days before declining in the late luteal phase.
Circulating allopregnanolone levels parallel those of its parent proge~terone.~~ Circulating THDOC levels also fluctuate during the menstrual cycle, with higher levels in the luteal ~h a s e .~l Overall. the serum levels of THDOC L are lower than those of allopregnanolone, so THDOC is likely to be less relevant to catamenial epilepsy, although it could contribute. An important unanswered question is whether the local brain synthesis of neurosteroids also fluctuates.
In addtion to withdrawal of the anticonvulsant effects of neurosteroids in association with the fall in progesterone at the time of menstruation, plasticity in GABA, receptors, the targets of neurosteroid action, could also play a role in the enhanced brain excitabdity that is presumed to underlie the increase in seizure susceptibility in penmenstrual catamenial epilepsy. The precise changes in brain GABA, receptor subunit expression occurring during the human menstrual cycle have not been determined. However, it is now well recognized that prolonged exposure to allopregnanolone in rats causes increased expression of the a4 GABA, receptor subunit in hippocampus, resulting in decreased benzodiazepine sensitivity of GABA, receptor current^.^^,^^ Although a4 can coassemble with $2 to form synaptic GABA, receptors, it preferentially coassembles with 6 to form nonsynaptic (perisynapticl extrasynaptic) GABA, receptors. Treatment of rats with allopregnanolone results in transient increased expression of the 6 subunit in hippocampus and increased benzodazepineinsensitive tonic ~u r r e n t .~~,~~ Progesterone also increases 6 subunit expression, likely as a result of conversion to allopregnanolone. The relevance of the increased 6 subunit expression for catamenial epilepsy is unclear, as 6 subunit increases may be transitory and followed by reduced expression with chronic exposures, as in pregnancy or in the prolonged luteal phase of the human menstrual cycle. Therefore, an important consequence of the incorporation of the normally low-abundance a4 subunit into synaptic GABA, receptors is that synaptic currents generated by these receptors have accelerated decay kinetics, so that there is less total charge transfer, which results in reduced inhibition." GABA, receptor-modulating neurosteroids cause a prolongation of the decay of GABA-mediated synaptic currents. Consequently, in the presence of high levels of allopregnanolone during the luteal phase, the acceleration due to a4 substitution is balanced.
However, when neurosteroids are withdrawn at the time of menstruation, synaptic inhibition is dminished from normal, resulting in enhanced excitability, which, among other effects, prechsposes to seizures. Indeed, chronic exposure to neurosteroids also is accompanied by downregulation of 6 subunit expression and perisynaptic/extrasynaptic GABA, receptor^.^^ This change is believed to be a compensatory mechanism, which would avoid excessive sedation caused by high neurosteroid levels acting on sensitive F subunit-containing GABA receptors. At the time of neurosteroid withtrawal, F subunit expression rapidly recovers. However, if recoverv is not sufficiently fast, there could be an enhancement of excitability due to a reduction in tonic inhibition mechated by perisynaptic/extrasynaptic GABA, receptors in the relative absence of neurosteroids.
A rodent model has been developed to simulate the hormonal changes that are believed to be relevant to perimenstrual catamenial e p i l e p~~.~~,~~ Rodents have a 4 to 5 day estrous cycle, and studies of fluctuations in seizure susceptibility in cycling female rodents have not led to results that are relevant to the human menstrual cycle. In order to provide a model that more closely mimics the human situation, a condtion of pseudopregnancy was induced in rats by sequential gonadotropin treatment. This resulted in prolonged h g h circulating levels of estrogen and progesterone similar to those that occur in the luteal ohase of the 28 dav L human menstrual cvcle. Then, to siinulate the withdrawal of allopregnanolone that occurs in conjunction with the fall in progesterone levels at the time of menstruation, the animals were treated with finasteride 11 days after the initiation of gonadotropin treatment.
The neurosteroid withdrawal model of catamenial epilepsy was used to investigate therapies for perimenstrual catamenid epilepsy.G3s9 A key result is that conventional antiepileptic drugs, i n c l u h g benzodazepines and valproate, have reduced potency in protecting against seizures during the period of enhanced seizure susceptibhty following neurosteroid withdrawal. This pharmacoresistance seems to mimic the situation in women with catamenid epilepsy in whch breakthrough seizures occur despite treatment with antiepileptic drugs. In contrast to the results with conventional antiepileptic drugs, neurosteroids, including allo~regnanolone, THDOC, and their 5P-isomers, were found to have enhanced activity in the periinenstrual catamenial epilepsy model.fi3 T h s suggested a "neurosteroid replacement" approach to treat catainenial seizure exacerbations.'" neurosteroid could be administered in a "pulse'" prior to menstruation and then withdrawn or continuously administered throughout the month. While intermittent administration at the time of increased seizure vulnerability is rational. continuous administration would avoid withdrakal of the therapeutic agent, which itself could predspose to seizures. This factor, as well as the practical chfficulty many women experience in premcting the time of their menstrual periods, suggests that continuous administration is preferred. The neurosteroid would be adnlinistered at low doses to avoid sedative side effects. Such low doses are expected to contribute little anticonvulsant activity during most of the menstrual cycle. Patients would still reauire treatment with conventional antie~i-1 L leptic medications. However, during the period of enhanced seizure susceptibility at the time of menstruation, the increased potency of the neurosteroid would confer protection against penmenstrual seizure exacerbations. It is noteworthy that while the anticonvulsant activity of neurosteroids increases in conjunction with neurosterold withdrawal, there is no correspondng increase in side effects (mainly sedation), at least as assessed by a measure of motor impairment." Therefore, enhanced side effects, whch would negate the potential of the therapeutic approach, would not be expected to occur.
To deternline whether the enhanced activity of neurosteroids is due to oharmacokinetic or L pharmacodynanic factors, brain and plasma levels of the neurosteroid ganaxolone (3~-hydroxy-3P-methyl-5a-pregnan-20-one, discussed below) were determined with a liauid chroma-1 tography-mass spectrometric method. Control and neurosteroid withdrawn animals received a single dose of ganaxolone (7 mgkg, subcutaneously), resulting in an elevation in PTZ threshold that peaked at 30 min and returned to baseline at 120-180 min. Ganaxolone caused a markedly greater (1.8-fold) elevation of the PTZ threshold in the withdrawn animals than in controls, indicating a greater sensitivity to the anticonvulsant effects of ganaxolone. Surprisingly, plasma and brain ganaxolone levels were reduced in withdrawn animals (69% of control levels). Adjusting for the reduced brain levels, the phamacdynmic sensitivity to ganaxolone was enhanced 2.3-fold in the withdrawn animals compared with controls. There was a significant increase in clearance (CL) of ganaxolone in the withdrawn animals, which accounts for the reduced plasma and brain levels. Ganaxolone levels reached a peak more slowly in brain (Tma9braun -30 min) than in plasma (T-p~,m,, -15 min); the TmW value corresponds with the peak elevation in seizure threshold. These studies confirmed the enhanced anticonvulsant activity of paxolone in the rat mode1 of catamenial epilepy. The enhanced activity occurs in the face of decreased plasma and brain ganaxolone levels, indicating a marked increase in pharmacodynamic sensitivity.
Recently, studes have been conductedwith the catmenial epilepsy model in femde rats that experienced a prolonged bout of status epilepticus induced by lithium-pilocarpine treatment, resulting in a chronic epileptic state with spontaneous recurrent seizures.g0 Epileptic animals in the catamenid epilepsy model exhibited about six seizures per day, each lasting appraximately 1 min. When neurosteroids were withdrawn by treatment with finasteride, an enormous (more than 10-fold) increme in seizure frequency was observed. In contrast, Enasteride did not induce seizures in normal animals. However, it did indude an increase in seizures in epileptic rats that were not treated with gonadotropins, albeit of smaller magnitude than that in the pseudopregnant animals. The observation that inhibition of the synthesis of endogenous neumsteroids in nonepileptic animals did not lead to seizures inJicates that neurosteroid reductions are not ~pileptogenic. This is consisteat with the observation that finasteride does not cause seizures in humans who do not have epilepsy. Finasteride is used clinically for the treatment of benign prostatic hypertrophy and male pattern hair loss. Seizures have not been reported as an adverse effect of the drug. While it is clear that finasteride does not provoke seizures in the general population, there are no prospective studies to determine whether inhibition of 5a-reductase by finasteride influences seizure susceptibility in individuals with epilepsy. There is a single anecdotal report of a woman with epilepsy taking finasteride for male pattern baldness who experienced an increase in seizure frequency and severity in association with finasteride use.Q1 The doses of finasteride used clinically are in the range of 1-5 muday, which are f a less than the doses of 39-190 rn@g used in rats to inhibit brain neurosteroid synthesis. Furthermore, in humans, finasteride is selective for the type 2 5a-reductase isoform and is less active on the type 1 enzyme that is the isofom predominantly present in the brain, This selectivity is not observed with the rat enzymes. In sum, finasteride, as admini3tered clinically in humans, probably does not block neurosteroidogenesis svfficiently to influence seizure susceptibdity under most circumstances. Also, individuals with eongenital 5a-reductase deficiency, caused by a mutation in the 5a-reductase type 2 gene (a conQtim with ambiguous genitalia), do not exhibit epilepsy. While neusosteroid reduction by itself does not lead to epilepsy, it is apparent that endogenous neurosteroids do moddate seizure susceptibility in epileptic animals.
Although it has been assumed that the effect of finateride on seizure susceptibility is mediated through inhibition of peripheral neurosteroidogenesis, ovariectomized epileptic animals also exhibited large increases in seizure frequency following finasteride treatment, indicating that a major effect of the drug may be to influence neurosteroid synthesis in the brain." Whatever the site of action of h a steride, treatment with exogenousrdIopregnanolone was found to rapidly terminate the hasteride-induced exacerbation of seizures, providing additional evidence that the increase in seizure ffequency is due to a finasteride-induced reduction in neurosteroids and not some other action of the drug. More importantly, it supports the concept tbat neurosteroid replacement may be useful in the treatment of seizures associated with neurosteroid fluctuations, such as catamenial epilepsy. In catamenid epilepsy, breakthrough seizures occur despite treatment with antiepileptic drugs. Previous studies (reviewed in ref. 88) and the new results from Lawrence et aLQO support the potential of neurosteroids as a novel treatment approach for these phamacoresistant seizures.
Although neurosteroids seems to be the most direct approach to the treatment of catamenial epilepsy, only limited anecdotal data are a v dable to support their use.g2 No neurosteroid is currently approved. In contrast, two openlabel trials have shown that adjunctive progesterone therapy produces significant reductions in seizure occurrence." It is recommended that the hormone be administered during the entire second half of the menstrual cycle and tapered gradually, as it is believed that abrupt discontinuation can result in rebound seizure exacerbation. Enthusiasm for the use of progesterone in the treatment of catamenial epilepsy has been tempered by the lack of data from adequately controlled clinical trials. A multicenter prospective controlled trial of 3 months of supplemental progesterone in 462 women, 294 who were randomized 2:l to progesterone or placebo, has been completed. While the overall response to progesterone was no greater than to placebo in women with or without catamenial epilepsy, as the magnitude of a woman's perimenstrual seizure exacerbation increased there was a correlated increase in the response to progesterone but not to placebo, suggesting that some women may benefit."* Progesterone therapy in women may cause hormonal effects such as breakthrough vaginal bleeding and breast tenderness as well as weight gain, sedation, and emotional depression. Neurosteroids, such as ganaxolone, have not been associated with such side effects and may ultin~ately prove to be superior as a treatment approach.
Neurosteroids and Stress-Induced Seizure Fluctuations
The availability of neurosteroids is increased during physiological stress. Stress results in the hypothalamic release of corticotropin-releasing hormone (CRH), whch liberates adrenocorticotropic hormone (ACTH) from the anterior pituitary. Along with cortisol, ACTH also enhances the synthesis of adrenal DOC,94g5 which is released into the circulation and can serve as a precursor for synthesis of the neurosteroid DOC (Fig. 77-1) . In contrast to allopregnanolone, which is present in the brain even after adrenalectomy and gonadectomy, THDOC appears to be derived nearly exclusively from adrenal source~.~~ Plasma and brain levels of THDOC and allopregnanolone rise rapidly following acute s t i -e~s .~~,~~ Acute stressors such as swimming, foot shock, or carbon dioxide exposure elicit an increase in allopregnanolone and THDOC concentrations in plasma and in brain.Q8 99 Stress-induced neurosteroids have been demonstrated to elevate the seizure threshold.52 Stress-induced seizure protection could be due to circulating neurosteroids svnthe-" sized in peripheral tissues or to those produced locally in the brain. However, the effects of swim stress-induced increases in seizure threshold and THDOC levels in rats were abolished in adrenalectomized animals, implicating adrenalderived THDOC. Despite stress-induced seizure nrotection in ani~nals.~"O%atients and cli-I nicians are not likely to recognize a reduction in seizure frequency associated with stress. Indeed, stress has been reported to trigger seizure activity in persons with e p i l e p~~.~~~J~* During stressful episodes adrenal hormone levels are expected to fluctuate, and it may simply be the withdrawal of THDOC d u r i n~ such fluctuations that is asso-0 ciated with seizure ~rovocation. Alternatively, other unidentified hknnonal factors with priconvulsant activity may be responsible for stressinduced increases in seizures. However, chronic stress of the type experienced by patients with epilepsy likely has dfferent endocrinological consequences than acute stress. The effects on seizures of fluctuations in neurosteroid levels in chronic stress remain to be studed.
Neurosteroids in Temporal Lobe Epilepsy
Sexual and renroductive dysfunction are L coininon among persons with epilepsy.lo5 In particular, men with temporal lobe epilepsy (TLE) often have diminished libido and sexual potency that is associated with low testosterone levels.106108 T h s hypogonadal state has been attributed to the effects of certain hepatic enzyme-inducing antiepileptic drugs, or dternativelv-given the extensive connec-, " tions between temporal lobe structures such as the amygdala and hypothalainic nuclei that govern the production and secretion of gonadotropin releasing hormone-to suppression of the hypothalamic-pituitary-gonadal axis by limbic seizures. There is evidence that serum androgen levels normalize after tem~oral lobe 0 I surgery that results in successful seizure con-" , trol but not in patients who continue to have seizures, supporting the view that seizures are responsible for the hypoandrongenic state.log Testosterone, as noted previously, is a precursor for at least three neurosteroids with anticonvulsant properties: 5a-androstane&ol, androsterone, and e t i o c h~l a n o l o n e .~~~~~
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There is evidence that serum levels of at least two of these steroids (androsterone and etiocholanolone) are reduced in men with epilepsy c o m~w e d with control subiects.lO"t is conceivable that reduced levels of such anticonvulsant neurosteroids lead to an enhanced propensity for seizures and that neurosteroid re~lacement I might be a useful therapeutic approach.
Certain biological factors in TLE may influence the sensitivity to endogenous neurosteroids and could have an i m~a c t on the efficacv 
GANAXOLONE AS A NOVEL NEUROSTEROID-BASED ANTIEPILEPTIC DRUG
Ganaxolone, the synthetic @-methyl derivative of allopregnanolone,l18 is the only neurosteroid that has been evaluated for the treatment of epilepsy in human^.^^,"^ Allopregnanolne itself has been administered to humans at low doses intravenously (0.05-0.09 mg/kg) and found to be largely free of side effects except for ~e d a t i o n . l~~J~' However, it has been proposed that allopregnanolone canundergo back conversion by 3a-HSOR isoenzymes to a hormonally active intermedate (dhydropr~gesterone).~~~
The 3P-methyl substituent of ganaxolone eliminates this back conversion, potentially avoidmg hormonal side effects. Other than this theoretical advantage, ganaxolone has pharmacological properties similar to those of the natural neurosteroid from which it is derived.
Preclinical Studies Neurosteroids and Alcohol Withdrawal Seizures
Ganaxolone has protective activity in diverse rodent seizure models, including clonic seiSystemic administration of moderate doses (1-2.5 zures induced by the chemoconvulsants g/kg) of ethanol causes increases in plasma and pentylenetetrazol, bicuculline, flurothyl, t-butylbicycloorthobenzoate, and aminophylline; limbic seizures in the 6 Hz model; amygdala-and cocaine-kindled seizures; and corneal kindled seizures (Table 77-1) . 62,6' ,12s1P6 In chronically treated rats, tolerance does not occur to the anticonvulsant activity of ganax~lone:~' In addltion, a recent study in female amygdalalundled mice demonstrated suppression of behavioral and electrographic seizures with a medlan effective dose (ED,,) of 6.6 n1g/kg.l2' Animal pharmacokinetic studies have found that ganaxolone has a large steady-state volume of distribution (6.5,7.0,19.5, and3.5 L/kg in mice, rats, rabbits, and dogs, respectively), indicating that it distributes extensively into tissues.75 Studies with radioactive ganaxolone in rats have found that ganaxolone (and its metabolites) are concentrated in tissues including the brain (brain-to-plasma concentration ratio between 5 and 10). Ganaxalone is highly bound to human plasma proteins (>99%). It is extensively metabolized to at least 16 different compounds; the primary metabolite is 16a-hydroxyganaxolone, which likely results from the action of CYP3A4. This primary metabolite is inactive in the PTZ seizure model and is 25-fold weaker than ganaxolone in inhibiting [35S]TBPS binding. Ganaxolone is a CYP3A4 autoinducer in rodents but not in dogs or humans; chronic exposure to high doses in female rats does cause liver hypertrophy. Metabolites of ganaxolone are eliminated in the urine (13%-23%) and feces (65%-76%) in rats and dogs; the corresponding values in inale healthy volunteers are 25% and 69%, respectively. Because of its aqueous insolubility, orally administered ganaxolone is poorly absorbed. To provide more consistent bioavailability, the steroid has been administered as a subinicron particulate suspension and in a proprietary solid formulation.
Animal safety studies have demonstrated little evidence of target organ or systemic toxicity with either single-dose or multiple-dose ganaxolone treatment. In studles on pre-and ~ostnatal development in mice, rats, and dogs, ganaxolone dld not affect fetal implantation, viability, or growth and development from birth to weaning and was not teratogenic. Genotoxicity tests have not demonstrated any mutagenic or clastogenic ~otential for ganaxolone. Oral administration of ganaxolone to conscious dogs at a dose of 10 mg/kg dld not reveal changes in cardiovascular hemodynainics.
Clinical Safety and Efficacy Studies
Over the past decade, ganaxolone has been studed in various clinical trials to assess its efficacy and safety in the treatment of epilepsy. More than 900 subjects have received the drug at doses of up to 1875 mg/day in adults and up to 54 mglkglday in cMdren in Phase 1 norinal volunteer studles, epilepsy trials, and also clinical trials for migraine. Single oral doses of 50-1600 mg in healthy volunteers results in peak plasma concentrations of 14 to as h g h as 460 ng/mL. Overall, the drug is safe and well tolerated. The most common side effect is three patients in this study were followed in an extension phase over 3.5 years.130 As discussed previously there is limited anecdotal information supporting the efficacy of ganaxolone in the treatment of catamenial seizure exacerbat i o n~. '~ Recently, a double-bhnd, randomized, placebo-controlled study was completed in adults with wartial seizure^.'^ A separate trial L was completed in infants with spasms. In this study, there was no clear statistically significant treatment effect, although some subjects did awwear to demonstrate a treatment-related
reduction in spasm clusters as assessed by 24 h video-electroencephalographic recorclngs. The adult trial included 147 subjects (100 females, 47 males), aged 18 to 69 years, with partial-onset seizures with or without secondary generalization who were refractory to conventional antiepileptic drugs. Subjects were randomized in a 2:l ratio to ganaxolone (1500 mg/day in three divided doses) or placebo. Ganaxolone treatment produced an 18% decrease in mean weeklv seizure freauencv i I i coinpared with a 2% increase for placebo over the 10 week treatment period (p = ,025).
Responder rates (proportions of subjects with greater than 50% reduction in seizures dur-0 ing the maintenance phase) were 26% for the ganaxolone group versus 13% for the placebo group. Results from the open-label extension whase indicated that ganaxolone maintains its U efficacy over time. Adverse events reported by at least 5% of patients, and at least twice as common in the ganaxolone group compared to the placebo group, were dizziness, fatigue (both 16% versus 8%), and somnolence (13% versus 2%). Seven percent of the subjects in the ganaxolone treatment group and 6% of those in the placebo group discontinued treatment due to adverse events.
CONCLUSIONS
Neurosteroids are endogenous modulators of neural excitability that are believed to have a role in the regulation of seizure susceptibility in the setting of preexisting epilepsy. Menstrual and stress-related fluctuations in seizures may i in part be related to changes in brain neurosteroid levels. In addition, men with TLE who have suppression of the hypothalamicpituitary-gonadal axis may have a reduction in testosterone-derived neurosteroids that could worsen seizures.
Treatment with exogenously administered natural neurosteroids or svnthetic analogs " such as ganaxolone may be beneficial to treat partial szizures. ~u r t h k r stucles are required to determine if neurosteroid replacement is a useful therapeutic approach for seizure exacerbations related to endogenous neurosteroid fluctuations, such as in catamenial epilepsy and stress. In the future, agents that influence the endogenous synthesis of neurosteroids, such as TSPO ligands, may find utility as an alternative to neurosteroids themselves in the treatment of epilepsy.24 131 
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